Physician

Elsy Viviana Navas, M.D

According to 2025 Medicare claims, Elsy Navas, M.D (NPI: 1447493275) practices advanced heart failure and transplant cardiology in the Naples-Marco Island, FL market, with the plurality of this provider's patient population coming from Collier, FL. This provider's primary affiliated billing organization is NCHMD INC (NPI: 1831120195; TIN: 331075317) and primary practice location at 34102-5754. Navas is affiliated with the NCH ACO, LLC (ACO ID: A3797), participating under the MSSP model.

Navas' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 681 traditional Medicare patients, billed 2,468 HCPCS/CPT codes, and received $229,944 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 2,404 prescription claims across 343 beneficiaries totaling $15,503,650 in drug costs, led by Vyndamax (Tafamidis). DME data shows 121 claims. Open Payments data shows 88 records totaling $55,655. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $111,335 to $229,944. Similarly, Part D prescription costs have moved sharply higher in recent years, from $126,279 to $15,503,650. In contrast, DME billing represents a smaller volume and moved sharply higher in recent years, from $13,420 to $23,968.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	485	1,033	$111,335
2016	598	1,338	$154,849
2017	503	1,188	$136,978
2018	535	1,396	$160,384
2019	453	1,368	$164,281
2020	300	1,091	$125,705
2021	312	938	$106,182
2022	432	1,818	$191,648
2023	580	2,170	$215,247
2024	681	2,468	$229,944

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	191	1,856	$126,279
2016	229	2,088	$143,474
2017	244	2,127	$190,916
2018	245	1,768	$161,922
2019	311	2,132	$431,723
2020	215	1,059	$777,088
2021	149	882	$814,749
2022	221	1,265	$1,977,110
2023	256	1,787	$4,667,334
2024	343	2,404	$15,503,650

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	137	$123,371
2016	N/R	310	$148,293
2017	N/R	373	$22,005
2018	N/R	301	$16,778
2019	N/R	289	$15,879
2020	N/R	287	$17,955
2021	N/R	156	$8,588
2022	N/R	19	$35,850
2023	N/R	N/R	N/R
2024	N/R	121	$13,082

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	183	183	$174
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	330	597	$142
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	206	239	$141
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	191	613	$96
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	238	347	$13

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Vyndamax	Tafamidis	429	15,210	$11,899,848
Amvuttra	Vutrisiran Sodium	14	1,242	$1,696,464
Vyndaqel	Tafamidis Meglumine	37	1,290	$936,281
Entresto	Sacubitril/Valsartan	327	18,357	$348,420
Jardiance	Empagliflozin	289	17,552	$332,614

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
A4222	Infusion supplies for external drug infusion pump, per cassette or bag (list drugs separately)	N	N/R	42	$10,620
J2260	Injection, milrinone lactate, 5 mg	N	N/R	42	$1,752
A4221	Supplies for maintenance of non-insulin drug infusion catheter, per week (list drugs separately)	N	N/R	37	$710

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	88	$55,655	Lexicon Pharmaceuticals, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Elsy Viviana Navas, M.D?

Tedicare shows public-source Medicare data for Elsy Viviana Navas, M.D (NPI 1447493275), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Elsy Viviana Navas, M.D have ACO affiliation data?

Elsy Viviana Navas, M.D is shown with ACO affiliation data for NCH ACO, LLC (MSSP, ACO ID A3797).

What billing organization is linked to Elsy Viviana Navas, M.D?

Elsy Viviana Navas, M.D is linked to NCHMD INC (billing NPI 1831120195) in the available physician profile data.

Does Elsy Viviana Navas, M.D have Open Payments data?

Elsy Viviana Navas, M.D has 88 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.